Anxiety disorders informants

Extrapolation to other countries is not easy. Canada has a very different health-care system to the USA. A small-scale study involving 466 anxiety disorder patients in Quebec established a clear relationship between the severity of the disorder and utilization of health services (McCusker et al, 1997). Patients with obsessive-compulsive disorder were particularly likely to seek treatment. No information on dmg use was presented. 

Inform patients of treatment options for anxiety disorders and the expected benefits of each (e.g., pharmacotherapy, psychotherapy, and combination treatment). 

How can good pharmacotherapists be found First, check with experienced and respected colleagues, take note of which pharmacotherapists are referring patients to you, attend local educational meetings with psychiatrists, or, if there is a medical school nearby, attend the psychiatry department s grand rounds. Local patient advocacy and support groups, such as the Depression and Bipolar Support Alliance (DBSA), the National Alliance for the Mentally HI (NAMI), the American Foundation for Suicide Prevention (AFSP), and the Anxiety Disorders Association of America (ADAA), are valuable sources of information from the patient s perspective. 

Buspirone (Buspar). Buspirone is an anxiety-relieving medication that alters serotonin activity. When added to an antidepressant, buspirone may help treat the depression. It will also relieve anxiety and may reverse sexual side effects of a SSRl. Please refer to Chapter 5 Anxiety Disorders for more information regarding buspirone. 

Tricyclic Antidepressants (TCAs). Because of their effectiveness not only for depression but for anxiety disorders such as panic disorder as well, TCAs were the first medications formally tested in the treatment of PTSD. Three TCAs, amitriptyline, imipramine, and desipramine, have been studied in small trials, producing modest benefit for reexperiencing and hyperarousal symptoms, without any relief of avoidance/numbing symptoms. Given this limited benefit in conjunction with the side effect burden and potential for toxicity in a suicide prone population, TCAs are infrequently used in the treatment of PTSD. Please refer to Chapter 3 for more information regarding TCAs. 

For more information regarding the use of MAOls please refer to Chapter 3 (Mood Disorders) and Chapter 5 (Anxiety Disorders). 

Table 2 summarizes Hfetime, 12-month, 6-month and point prevalence findings for anxiety disorders across major commimity studies that have been conducted since the introduction of the DSM-III in 1980. Table 2 in addition provides information about diagnostic criteria, instriunents used, and sample... 

Here we shall summarize the neurobiology of adult depression and anxiety disorders and compare these findings to the consequences of early-life stress. For information on the neurobiology of childhood mental disorders, we refer to Part I-C in this book. Notably, there are marked differences in the neurobiology of childhood depression, as compared to adulthood depression, and there appears to exist a subtype of childhood depression that is related to early trauma and has a distinct neurobiology. 

There are no controlled studies and little open data to inform use of beta-blockers in treatment of pediatric anxiety disorders. 

Available pharmacokinetic (PK) studies of medications with potential to treat pediatric anxiety disorders have been open studies that examine PK parameters and monitor adverse effects in children and adolescents. None of the pediatric PK studies described below were designed as dose finding studies, and none of the studies were able to describe a clear association between dose or exposure and specific adverse effect. However, pediatric PK data can be useful to guide dosing and adverse effect monitoring to the extent that the weight-adjusted PK parameters inform extrapolation based on comparable studies of adult PK. The following summary of PK studies is based on multiple-dose PK studies. 

The commonly used classes of antidepressants are discussed in the following sections, and information about doses and half-lives is summarized in Table 2-1. The antidepressant classes are based on similarity of receptor effects and side effects. All are effective against depression when administered in therapeutic doses. The choice of antidepressant medication is based on the patient s psychiatric symptoms, his or her history of treatment response, family members history of response, medication side-effect profiles, and comorbid disorders (Tables 2-2 and 2-3). In general, SSRIs and the other newer antidepressants are better tolerated and safer than TCAs and MAOIs, although many patients benefit from treatment with these older drugs. In the following sections, clinically relevant information is presented for the antidepressant medication classes individually, and the pharmacological treatment of depression is also discussed. The use of antidepressants to treat anxiety disorders is addressed in Chapter 3. 

The parallel-group, double-blind, placebo-controlled study design represents the golden standard of acute treatment trials of depression, mania and anxiety disorders. This design is intended to limit bias, in particular selection and measurement bias. Trials based on this design are expected to provide information about the effect size of a new compound and its side-effect profile. 

This chapter deals with the question of how psychotropic drugs act upon cognitive functions in man. Some of the pertinent information, i.e. how single doses of these pharmaceuticals affect cognitive performance in healthy volunteers under experimental conditions, has been reviewed and discussed in Chapter 3. However, when dealing with drug effects in patients suffering from schizophrenia, depression, anxiety disorders, etc. one must expect a much... 

Particularly in more serious cases, medications are often used to supplement the treatment regimen, because they allow the client to do the necessary therapeutic work (Schatzberg Cole, 1991). This is especially important when such great strides have been reported in the use of cognitive-behavioral treatments to treat symptoms of depression and anxiety. Because many of these interventions relate to depression and anxiety, more in-depth information on cognitive-behavioral interventions is covered in chapter 6 on anxiety disorders. 

This chapter presents an overview of the knowledge and skills necessary to treat clients with anxiety disorders, and it encourages social workers to seek additional information on these disorders and their treatments. Given the rapidly changing health and mental health practice environments, social workers must stay abreast of new trends and therapeutic strategies in the mental health field. 

---